LAURUSLABS2018-07-012018-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LAURUSLABS2018-07-012018-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LAURUSLABS2018-07-012018-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member LAURUSLABS2018-07-012018-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member LAURUSLABS2018-07-012018-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member LAURUSLABS2018-07-012018-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares LAURUSLABS 2018-04-01 2019-03-31 2018-10-23 INR Millions Half yearly Single segment Pharmaceutical 2018-07-01 2018-09-30 Unaudited Consolidated 5882810000.00 105280000.00 5988090000.00 3265920000.00 58310000.00 -177840000.00 734750000.00 246450000.00 398180000.00 1244410000.00 5770180000.00 217910000.00 0.00 217910000.00 30610000.00 25200000.00 55810000.00 0.00 162100000.00 0.00 0.00 0.00 0.00 162100000.00 -56720000.00 105380000.00 0.00 0.00 0.00 0.00 1064370000.00 10 1.53 1.53 0.00 0.00 1.53 1.53 Notes: 1. The above unaudited consolidated financial results of Laurus Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on November 01, 2018. The statutory auditors of the Company have carried out a limited review on the consolidated financial results and expressed an unmodified audit opinion thereon.(For full notes, please see the signed financial results sheet) 2018-04-01 2018-09-30 Unaudited Consolidated 11272980000.00 131150000.00 11404130000.00 6148110000.00 85300000.00 -135540000.00 1462870000.00 469680000.00 780110000.00 2149450000.00 10959980000.00 444150000.00 0.00 444150000.00 76150000.00 40320000.00 116470000.00 0.00 327680000.00 0.00 0.00 0.00 0.00 327680000.00 -70470000.00 257210000.00 0.00 0.00 0.00 0.00 1064370000.00 10 3.09 3.08 0.00 0.00 3.09 3.08